Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b randomized, double-blind placebo-controlled study of ENTR-601-44 non-ambulatory and ambulatory adult patients with DMD who are exon 44 skipping amenable

Next Previous
Trial Profile

A Phase 1b randomized, double-blind placebo-controlled study of ENTR-601-44 non-ambulatory and ambulatory adult patients with DMD who are exon 44 skipping amenable

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ENTR-601-44 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms ELEVATE-44-102

Most Recent Events

  • 06 Oct 2025 According to an Entrada Therapeutics media release,The study will be conducted in the U.S. and is on track to initiate in the first half of 2026.
  • 27 Feb 2025 According to an Entrada Therapeutics media release, the company have submitted regulatory filings to initiate a global Phase 1/2 MAD clinical study of ENTR-601-45 ,also on a track to initiate ELEVATE-44-201 in the U.K. in Q2 2025.
  • 26 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top